Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Undervalued vs peers
About
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA,
Target Price
The average target price of GRF.MC is 14 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell